First Trust Advisors LP Trims Stake in Astera Labs, Inc. $ALAB

First Trust Advisors LP cut its position in Astera Labs, Inc. (NASDAQ:ALAB) by 24.3% in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 238,949 shares of the company’s stock after selling 76,677 shares during the quarter. First Trust Advisors LP’s holdings in Astera Labs were worth $26,189,000 at the end of the most recent quarter.

Other hedge funds have also recently added to or reduced their stakes in the company. Atreides Management LP increased its position in Astera Labs by 2,496.6% during the fourth quarter. Atreides Management LP now owns 1,611,194 shares of the company’s stock worth $268,038,000 after buying an additional 1,549,144 shares during the period. Amundi grew its position in shares of Astera Labs by 1,298.6% during the third quarter. Amundi now owns 1,421,263 shares of the company’s stock worth $278,283,000 after acquiring an additional 1,319,643 shares during the last quarter. Artisan Partners Limited Partnership purchased a new position in shares of Astera Labs during the fourth quarter worth approximately $148,980,000. Goldman Sachs Group Inc. increased its holdings in shares of Astera Labs by 189.0% in the 4th quarter. Goldman Sachs Group Inc. now owns 1,312,927 shares of the company’s stock valued at $218,419,000 after acquiring an additional 858,693 shares during the period. Finally, State Street Corp increased its holdings in shares of Astera Labs by 32.5% in the 4th quarter. State Street Corp now owns 3,099,809 shares of the company’s stock valued at $515,684,000 after acquiring an additional 760,358 shares during the period. Hedge funds and other institutional investors own 60.47% of the company’s stock.

Insider Buying and Selling

In other Astera Labs news, COO Sanjay Gajendra sold 400,000 shares of Astera Labs stock in a transaction that occurred on Thursday, May 21st. The stock was sold at an average price of $290.30, for a total value of $116,120,000.00. Following the sale, the chief operating officer owned 5,064,213 shares of the company’s stock, valued at approximately $1,470,141,033.90. The trade was a 7.32% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Manuel Alba sold 136,974 shares of the business’s stock in a transaction that occurred on Wednesday, July 1st. The stock was sold at an average price of $442.01, for a total value of $60,543,877.74. Following the transaction, the director owned 1,287,524 shares in the company, valued at $569,098,483.24. The trade was a 9.62% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 1,676,845 shares of company stock valued at $444,928,806 over the last ninety days. Corporate insiders own 10.40% of the company’s stock.

Astera Labs Stock Performance

Shares of ALAB opened at $260.23 on Wednesday. The stock has a market capitalization of $44.61 billion, a P/E ratio of 175.83, a P/E/G ratio of 3.27 and a beta of 3.66. Astera Labs, Inc. has a 1 year low of $97.89 and a 1 year high of $499.48. The company’s fifty day moving average is $360.60 and its two-hundred day moving average is $227.59.

Astera Labs (NASDAQ:ALAB) last released its earnings results on Tuesday, May 5th. The company reported $0.61 EPS for the quarter, topping the consensus estimate of $0.54 by $0.07. The company had revenue of $308.36 million during the quarter, compared to analysts’ expectations of $292.19 million. Astera Labs had a net margin of 26.72% and a return on equity of 18.49%. The business’s revenue was up 93.5% on a year-over-year basis. During the same quarter last year, the business earned $0.33 EPS. Astera Labs has set its Q2 2026 guidance at 0.680-0.700 EPS. Sell-side analysts predict that Astera Labs, Inc. will post 1.86 EPS for the current year.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on ALAB. UBS Group increased their price target on shares of Astera Labs from $205.00 to $400.00 and gave the stock a “neutral” rating in a research note on Monday, June 29th. TD Cowen upped their target price on shares of Astera Labs from $225.00 to $425.00 and gave the company a “hold” rating in a report on Monday, July 13th. Stifel Nicolaus increased their target price on shares of Astera Labs from $260.00 to $460.00 and gave the stock a “buy” rating in a research note on Wednesday, June 24th. Evercore reissued an “outperform” rating and set a $297.00 price target on shares of Astera Labs in a report on Tuesday, May 19th. Finally, Needham & Company LLC boosted their price target on Astera Labs from $220.00 to $260.00 and gave the company a “buy” rating in a research report on Wednesday, May 6th. Twelve equities research analysts have rated the stock with a Buy rating and eleven have assigned a Hold rating to the stock. According to data from MarketBeat.com, Astera Labs has an average rating of “Moderate Buy” and an average price target of $282.00.

About Astera Labs

Astera Labs is a fabless semiconductor company that develops connectivity solutions for data center and cloud infrastructure. The firm focuses on addressing signal integrity and link management challenges that arise as server architectures incorporate higher-bandwidth processors and accelerators. Its technology is aimed at improving reliability and performance for high-speed interconnects used in servers, storage systems and compute accelerators.

The company’s product portfolio centers on silicon devices and accompanying firmware and software that enhance and manage high-speed links.